Your browser doesn't support javascript.
loading
In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism.
Allorge, D; Harlow, J; Boulet, O; Hayhurst, G P; Chowdry, J; Roth, E; Crewe, K; Lo-Guidice, J M; Lhermitte, M; Broly, F; Tucker, G T; Ellis, S W.
Afiliación
  • Allorge D; Faculté de Médecine/Pôle Recherche, Lille, France.
Pharmacogenetics ; 11(8): 739-41, 2001 Nov.
Article en En | MEDLINE | ID: mdl-11692084
From 10 to 30% of CYP2D6 ultra-rapid metabolizers of Caucasian origin harbor alleles with duplicated or amplified functional CYP2D6 genes. Recently, the CYP2D6*35 allele has been reported to be more frequent in ultra-rapid metabolizing subjects than in extensive metabolizers, suggesting a possible role of this variant in CYP2D6 duplication-negative ultra-rapid metabolizing subjects. In this study, we examined the functional consequences of the Val11Met, Arg296Cys and Ser486Thr amino acid substitutions associated with the CYP2D6*35 on the expression and catalytic activity of the variant enzyme, heterologously expressed in yeast. Our results indicate that the functional activity and level of expression of recombinant CYP2D6.35 are comparable with those of the wild-type enzyme, thus precluding the hypothesis that the high level of enzyme activity in CYP2D6 duplication-negative ultra-rapid metabolizing subjects is a consequence of the expression of a more catalytically effective CYP2D6.35 enzyme.
Asunto(s)
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Citocromo P-450 CYP2D6 / Alelos Límite: Humans Idioma: En Revista: Pharmacogenetics Año: 2001 Tipo del documento: Article País de afiliación: Francia
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Citocromo P-450 CYP2D6 / Alelos Límite: Humans Idioma: En Revista: Pharmacogenetics Año: 2001 Tipo del documento: Article País de afiliación: Francia